Inebilizumab for children with generalized myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study tests a new drug called inebilizumab for children with generalized myasthenia gravis (gMG), a condition causing muscle weakness. The drug aims to reduce the immune system's attack on nerves, which may improve symptoms. The study will check how safe and effective it is for young patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child must be aged 2 to 17 years old
- Diagnosed with generalized myasthenia gravis with a positive antibody test (AChR or MuSK)
- Disease severity classified as Class II, III, or IV
- Must be on stable doses of current treatments (steroids or certain immunosuppressants)
- No thymectomy (thymus removal) within the past 12 months
- No prior use of certain B-cell depleting therapies (like rituximab) in the past 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called gefurulimab in children and teens with generalized myasthenia gravis (a disease that causes muscle weakness). It looks at how safe and effective the drug is, and how it works in the body.
This trial studies how efgartigimod (given through a vein) behaves in children and whether it is safe and effective for generalized myasthenia gravis. It is designed for children who have not done well enough with standard treatments like steroids or other immune medicines.
This study gives an injectable medicine called zilucoplan to children who were part of an earlier trial and could benefit from more treatment. It aims to see if zilucoplan is safe and helpful for young patients with generalized myasthenia gravis.
This study tests a new daily shot (zilucoplan) for children and teens with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. It aims to see if the drug is safe and helps improve strength and daily functioning.
This trial tests an investigational drug called SHR-2173, given as an injection, for people with generalized myasthenia gravis. It aims to see if the drug can improve muscle strength and daily function.
This study tests an investigational drug called efgartigimod for children and teens with generalized myasthenia gravis. It may help those who haven't responded well enough to standard treatments.
Hear when a new Generalized Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.